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ABSTRACT
Microtubule-targeting agents (MTAs) are largely administered in adults and 
children cancers. Better deciphering their mechanism of action is of prime importance 
to develop more convenient therapy strategies. Here, we addressed the question of 
how reactive oxygen species (ROS) generation by mitochondria can be necessary 
for MTA efficacy. We showed for the first time that EB1 associates with microtubules 
in a phosphorylation-dependent manner, under control of ROS. By using phospho-
defective mutants, we further characterized the Serine 155 residue as critical for 
EB1 accumulation at microtubule plus-ends, and both cancer cell migration and 
proliferation. Phosphorylation of EB1 on the Threonine 166 residue triggered opposite 
effects, and was identified as a requisite molecular switch in MTA activities. We then 
showed that GSK3β activation was responsible for MTA-triggered EB1 phosphorylation, 
resulting from ROS-mediated inhibition of upstream Akt. We thus disclosed here a 
novel pathway by which generation of mitochondrial ROS modulates microtubule 
dynamics through phosphorylation of EB1, improving our fundamental knowledge 
about this oncogenic protein, and pointing out the need to re-examine the current 
dogma of microtubule targeting by MTAs. The present work also provides a strong 
mechanistic rational to the promising therapeutic strategies that currently combine 
MTAs with anti-Akt targeted therapies.
INTRODUCTION
Mitochondria are dynamic organelles that are 
organized in cells as a network closely connected to 
microtubules. They constitute a major source of Reactive 
Oxygen Species (ROS), which can form as a natural 
byproduct of the normal metabolism of oxygen through 
oxidative phosphorylation. ROS mainly consist in 
superoxide anion radical (O2.-), hydroxyl radical (OH
.) 
and hydrogen peroxide (H2O2). Among them, H2O2 acts 
as a second messenger for many cellular processes such 
as migration, proliferation and differentiation [1-3]. 
While a basal level of ROS is essential for cell viability, 
a mitochondria-governed oxidative stress has been linked 
to cell death induction through the intrinsic apoptotic 
pathway [4-5] and to mitochondrial network fragmentation 
that contributes to cell dysfunctions [6-7]. This growing 
set of data paved the way for new strategies that take 
into account the functional capacity of mitochondria to 
produce ROS in cancer cells, and that aim at interfering 
with mitochondrial energetics to improve cancer treatment 
[8-9].
Microtubule-Targeting agents (MTAs) are a 
broad group of anticancer drugs that are currently 
administered in a large range of indications in adults and 
children. It is well established that MTAs activate the 
intrinsic apoptotic pathway, and especially mitochondria 
membrane permeabilization and cytochrome c release 
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[extensively reviewed in 10-11]. MTA anti-mitochondrial 
activities can result from a modulation of Bcl-2 family 
members’ expression levels [12-14] or from a direct 
targeting of mitochondrial membranes [15-16]. MTAs are 
largely described to primary alter microtubule dynamic 
instability, resulting in suppression of both essential 
mitotic and interphase processes, such as cell proliferation, 
polarization and migration [17-19]. A growing set of data 
shows that MTA efficacy depends on microtubule plus end-
tracking proteins (+TIPs), which control multiple aspects 
of microtubule dynamic instability [20-21]. The End-
Binding protein 1 (EB1) forms comet-like accumulation 
at the growing microtubule plus-ends – by recognizing 
the GTP-cap and tubulin conformational intermediate 
states induced by GTP hydrolysis [22-23] – and plays 
a central role in assembly of +TIPs complexes [24-25]. 
The physiological functions of EB1 have been largely 
reviewed in a variety of microtubule-mediated cellular 
activities, including migration and cell division [26-27]. 
In addition, EB1 is overexpressed in several cancers 
[28-29] and we recently showed that this overexpression 
selectively sensitized glioblastoma to in vitro and in vivo 
MTA treatment (Berges et al., submitted). Our previous 
works also reported that alteration of EB1 accumulation 
at microtubule plus-ends was a fundamental event in MTA 
mechanism of action [30-32]. The intracellular machinery 
responsible for regulation of EB1 binding at microtubules 
is still under extensive investigations and discussions. 
Recent studies reported phosphorylation of EB3, another 
member of the EB family [33-34], increasing the range of 
+TIPs subjected to this post-translational modification [35-
36]. While a phosphorylation of EB1 homologues (Bim1p 
and Mal3) has been pointed out in budding and fission 
yeasts [37-38], this process has not been yet identified in 
mammalian cells. 
To date, the role of mitochondrial ROS in 
microtubule dynamics regulation has never been evaluated. 
However, in 2010, Smith [39] showed that an exogenous 
H2O2-mediated oxidative stress led to EB1 release from 
microtubule plus-ends, in cervix adenocarcinoma cells 
and cardiomyocytes from mice. Here, we aimed at 
characterizing the influence of mitochondrial ROS on 
microtubule dynamics and functions, and its involvement 
in cell response to MTA chemotherapy. We first showed 
that mitochondrial ROS overproduction was determining 
for MTA-mediated alteration of EB1 accumulation 
and cell response to drug cytotoxic and anti-migratory 
activities, in cancer cells of various tissue origins. We then 
highlighted that EB1 was subjected to phosphorylation, 
which regulates its ability to bind to microtubules. We 
further characterized Serine 155 and Threonine 166 as 
the potential phosphorylated residues, which exerted 
distinct effects on EB1 accumulation and microtubule 
dynamics. GSK3β activation, that resulted from ROS-
mediated inhibition of Akt, was lastly identified as 
responsible for MTA-triggered EB1 phosphorylation. 
Altogether, our results revealed a novel signaling pathway 
between mitochondria and microtubules, which could 
have high potential for therapeutic strategies and better 
understanding of cellular processes.
RESULTS
Mitochondrial ROS overproduction governs MTA 
cytotoxic and anti-migratory activities.
To evaluate the ability of MTAs to modulate 
mitochondrial ROS generation, several human cancer 
cell lines were used, originating from non-small cell 
lung carcinoma (A549), neuroblastoma (SK-N-SH), 
and glioblastoma (U87-MG). As shown in Fig.1A, 2nM 
vincristine, paclitaxel and patupilone (i.e. representative 
of the main MTA sub-classes used in the clinic at 
concentrations around IC50 in vitro) promoted O2
.- 
production in the three cell lines. For example, in SK-N-
SH cells, O2
.- production by mitochondria was increased 
by 36.6 ± 4.5 % after a 6 h-treatment with vincristine, 
and was maintained to a similar level after 24 h (32.9 ± 
2.7 %; p<0.01). In agreement, H2O2 intracellular levels 
were significantly increased by MTAs, whatever the 
cancer cell line evaluated (Fig.1B and Supplementary 
Fig.1A). The anticancer drugs were then combined to 
KCN, rotenone or tiron. These co-incubations resulted 
in the entire suppression of O2
.- and H2O2 overproduction 
leading to ROS basal level return whatever the inhibitor 
used (Fig.1B and Supplementary Fig.1B). To definitely 
ascertain the mitochondrial origin of the MTA-triggered 
ROS overproduction, we developed mtDNA-mutated ρ(-)
SK-N-SH cells, that were characterized by a decrease in 
ROS production from mitochondria (– 29 ± 3 %; p<0.001; 
Fig.1C). Unlike parental wtSK-N-SH cells, ρ(-)SK-N-SH 
cells were unable to overproduce O2
.- after a 6 h-treatment 
with vincristine (Fig.1C). Altogether, these data clearly 
show that MTAs share the capacity to selectively enhance 
ROS generation from mitochondria in different human 
cancer cell lines.
To specify the role of ROS overproduction in 
MTA activity, we first measured the drug effects on wt 
and ρ(-)SK-N-SH cell survival. As shown in Fig.1D and 
Supplementary Fig.1C, ρ(-)SK-N-SH cells were highly 
resistant to a 72 h-treatment with vincristine or patupilone. 
Even concentrations that caused up to a 90 % decrease in 
wtSK-N-SH cell survival remained ineffective in ρ(-)SK-
N-SH cells. Consistently, the time-dependent induction 
of A549 cell death by vincristine was suppressed when 
combined with tiron (Fig.1E and Supplementary 
Fig.1D). Transwell® assays further revealed that ROS 
overproduction was also essential for the anti-migratory 
effects of MTAs. These experiments have been performed 
in U87-MG cells, since glioblastoma are among the 
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Figure 1: Mitochondrial ROS overproduction governs MTA cytotoxic and anti-migratory activities. (A) Relative 
production of superoxides by WST-1 assay in A549, SK-N-SH and U87-MG cells during vincristine, paclitaxel or patupilone treatment at 2 
nM at 6 and 24 h. (B) Relative generation of hydrogen peroxide by the H2DCFDA fluorescence test in A549 and SK-N-SH cells incubated 
with 2 nM of vincristine, paclitaxel or patupilone, ROS inhibitors/scavengers or their combination for 6 h (MTAs are compared to control, 
while combinations are compared to MTAs alone). (C) Relative production of superoxides measured by WST-1 assay in wtSK-N-SH and 
ρ(-)SK-N-SH cells treated with 2 nM vincristine for 6 h. (D) wtSK-N-SH and ρ(-)SK-N-SH cell survival revealed by the MTT test after a 
72 h-exposition to vincristine. (E) Detection of apoptosis by flow cytometry analysis of annexin-V and propidium iodide staining in A549 
cells treated with vincristine (2nM), tiron or their combination for 24 and 48 h. (F) Measurement of transwell migration in U87-MG cells 
in the presence of 2 nM of vincristine or patupilone, tiron or their combination for 6 h. Data are presented as mean ± S.E.M. Student’s t-test 
*, p<0.05; **, p<0.01.
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most invasive cancers. As shown in Fig.1F, vincristine 
and patupilone treatment significantly decreased cell 
migration, by 34 ± 6 % (p<0.05) and 40 ± 3 % (p<0.01) 
respectively. However, when combined with tiron, MTAs 
did not display anti-migratory properties anymore. 
Inhibition of mitochondrial ROS overproduction is thus 
a source of cell resistance to both cytotoxic and anti-
migratory effects of treatment.
ROS overproduction by MTAs is responsible for 
inhibition of EB1 accumulation at microtubule 
plus-ends.
MTAs are known to affect cell proliferation 
and migration via inhibition of EB1 accumulation at 
microtubule plus-ends and alteration of microtubule 
Figure 2: MTA-mediated ROS overproduction inhibits EB1 accumulation at microtubule plus-ends. (A) Double indirect 
immunofluorescence staining of EB1 (red) and α–tubulin (green) in A549 cells incubated with 2 nM of vincristine, paclitaxel or patupilone 
for 6 h. Scale bars, 20μm. Magnified images: Scale bars, 5μm. (B) Quantification of EB1 comet length in A549 cells treated with MTAs 
and/or antioxidants for 6 h. Scale bars, 2.5μm. (MTAs are compared to control while combinations are compared to MTAs alone). (C) 
Immunofluorescence staining of EB1 and quantification of EB1 comet length in wtSK-N-SH and ρ(-)SK-N-SH under 6 h-treatment of 
vincristine at 2nM. Scale bars, 10μm. Magnified images: Scale bars, 2.5μm. Data are presented as mean ± S.E.M. Student’s t-test **, 
p<0.01; ***, p<0.001.
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dynamics instability. Here, we intended to understand 
whether mitochondrial ROS are be involved in such 
processes caused by MTAs. Confocal microscopy revealed 
a typical pattern of EB1 with comet-like structures at the 
plus-ends of microtubules in A549 control cells (Fig.2A, 
control panels). As expected, treatment with MTAs for 6 
h significantly inhibited EB1 accumulation at microtubule 
plus-ends (Fig.2A). Measurement of EB1 comets yielded 
a length from 2.7 ± 0.1 µm in control cells to 1.4 ± 0.1, 0.8 
± 0.1 and 1.0 ± 0.1 µm respectively in cells incubated with 
paclitaxel, vincristine and patupilone (p<0.01) (Fig.2B). 
It is noteworthy that EB1 expression level was not 
Figure 3: Phosphorylation of EB1 modulates its microtubule binding, microtubule dynamics and the microtubule-
governed cell functions. (A) Immunoprecipitation (IP) was performed in U87-MG and A549 cell lysates with anti-EB1 monoclonal 
antibody and the precipitates were analysed by western blot probed with anti-phosphoprotein total and anti-EB1 antibodies. (B) Western 
Blot analysis of EB1 expression in wtEB1-GFP, EB1 T166A-GFP, EB1 S155A-GFP transfected U87-MG cells. Parental U87-MG wild 
type (wt) was used as a negative control and α–tubulin was used as loading control. (C) Representative images and quantification of EB1 
comet length in U87-MG cells transfected with wtEB1-GFP, EB1 T166A-GFP and EB1 S155A-GFP. Scale bars, 2.5μm. (D) Measurement 
of transwell migration in EB1 T166A and EB1 S155A U87-MG transfected cells, expressed as a percentage of transmigrated cells in wtEB1 
cells. Panel shows representative images of the lower surface filter taken with an Olympus microscope. Scale bars, 200µm. (E) Proliferation 
assay in wtEB1, EB1 T166A and EB1 S155A U87-MG transfected cells. Data are presented as mean ± S.E.M. Student’s t-test *, p<0.05; 
**, p<0.01; ***, p<0.001.
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modulated by MTA treatment (Supplementary Fig.2A), 
strongly suggesting that EB1 proteins were delocalized at 
the microtubule plus-ends. We then evaluated the impact 
of KCN and tiron on EB1 localization in A549 cells. 
Interestingly, their simultaneous combination with MTAs 
prevented drug-induced EB1 delocalization (Fig.2B). For 
instance, the impact of vincristine on EB1 comet length 
was limited to 30 % when combined with KCN and 
totally suppressed by tiron. These results were similarly 
obtained in U87-MG and SK-N-SH cells (Supplementary 
Fig.2B, 2C and data not shown). It should be noticed that 
treatment with tiron alone increased the length of EB1-
decorated plus-end of microtubules by 23 % in A549 cells 
(Fig.2B) and by 13 % in U87-MG cells (Supplementary 
Fig.2C), strengthening the link between intracellular ROS 
levels and EB1 ability to accumulate at microtubule plus-
ends.
To further confirm these unexpected results, we 
measured EB1 comet length in wt and ρ(-)SK-N-SH 
cells. Consistently with the 29 ± 3 % decrease in basal 
mitochondrial O2
.- levels (Fig.1C), comet length was 
increased in ρ(-)SK-N-SH cells to 2.8 ± 0.2 µm (Fig.2C), 
as compared with the parental wt cells (1.7 ± 0.1 µm; 
p<0.001). We also quantified the median number of EB1 
comets per cell, that increased from 160 ± 10 in wtSK-
N-SH cells to more than 270 ± 22 in ρ(-) cells suggesting 
that number of growth microtubules increased (data 
not shown). Vincristine treatment (for 6 h), which was 
highly effective in wtSK-N-SH cells, caused a complete 
disappearance of EB1 accumulation at microtubule plus-
ends in 88 % of the cell population (data not shown). In 
cells that still contained EB1 comets, vincristine decreased 
their length from 1.7 ± 0.1 µm to 1.0 ± 0.1 µm (p<0.001; 
Fig. 2C). Interestingly, in ρ(-)SK-N-SH cells, vincristine 
did neither alter EB1 comet length (2.8 ± 0.2 to 2.4 ± 
0.1 µm; p>0.05) nor comet number (data not shown) in 
the majority of cell population (92 % of cells; data not 
shown). These data definitely involve ROS generation 
by mitochondria in regulation of EB1 accumulation at 
microtubule plus-ends.
Phosphorylation of EB1 regulates its accumulation 
at microtubule plus-ends, microtubule dynamics 
and microtubule-governed cell functions.
A growing body of evidence has recently 
demonstrated that +TIPs, including EB3, can be subjected 
to phosphorylation. To analyze whether such a process 
could be responsible for changes in EB1 accumulation 
at microtubule plus-ends, we performed EB1 
immunoprecipitation associated with anti-phosphoprotein 
antibody. For the first time, we found a phosphorylated 
form of EB1 in U87-MG cell lysates (Fig.3A, left panel). 
We also revealed that EB1 phosphorylation was suppressed 
by the O2
.- scavenger tiron. This ROS-dependent post-
translational modification of EB1 was then confirmed in 
A549 cells (Fig.3A, right panel). Since tiron also increased 
EB1 comet length (see Fig.2B and Supplementary Fig.2C), 
one can reasonably hypothesize that phosphorylation may 
control EB1 ability to form comets at microtubule plus-
ends. Using PhosphoSite, we thus generated constructs 
encoding for phospho-defective human EB1 protein, via 
substitution of threonine 166 or serine 155 residues by 
an alanine residue. We first ascertained that endogenous 
EB1 expression was repressed in favor of exogenous EB1-
Table 1: Measurement of EB1 comet length in wtEB1-GFP, EB1 T155A-GFP and EB1 
S166A-GFP transfected U87-MG cells treated with vehicle (control) or vincristine 2 nM 
for 6 h. Data are presented as mean ± S.E.M. Student’s t-test ****, p<0.001; NS, p>0.05.
EB1 comet length (µm) control vincristine vincristine vs control
wtEB1 2.5 ± 0.1 1.0 ± 0.1 - 60 % ***
T166A 3.9 ± 0.1 3.4 ± 0.1 - 13 % NS
S155A 1.9 ± 0.1 1.0 ± 0.1 - 47 % ***
Table 2: Measurement of microtubule dynamics parameters by live microscopy of EB1 at microtubule plus-ends 
in wtEB1-GFP, EB1 T155A-GFP and EB1 S166A-GFP transfected U87-MG cells exposed to vehicle (control) or 
vincristine 2 nM for 6 h. EB1 comets were tracked over time to measure microtubule growth rate and catastrophe frequency. 
Data are presented as mean ± S.E.M. Student’s t-test *, p<0.05; **, p<0.01; ***, p<0.001; NS, p>0.05.
variables control vincristine vincristine vs control
Growth rate (µm.min-1) 10.6 ± 0.4 7.5 ± 0.5 - 30 % ***
wtEB1 Catastrophe frequency (µm-1) 1.0 ± 0.1 1.7 ± 0.1 + 65 % ***
Decoration time (s) 14.2 ± 0.1 8.0 ± 0.3 - 56 % ***
Growth rate (µm.min-1) 15.9 ± 0.6 15.9 ± 0.7 < 1 % NS
T166A Catastrophe frequency (µm-1) 0.7 ± 0.1 0.9 ± 0.1 + 26 % *
Decoration time (s) 14.7 ± 0.2 12.8 ± 0.3 - 13 % NS
Growth rate (µm.min-1) 12.5 ± 0.5 8.5 ± 0.7 - 31 % ***
S155A Catastrophe frequency (µm-1) 0.9 ± 0.1 1.5 ± 0.2 + 56 % **
Decoration time (s) 9.0 ± 0.1 7.0 ± 0.2 - 23 % *
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GFP in the stably transfected U87-MG cells with the EB1 
T166A-GFP, EB1 S155A-GFP, and non-mutated wtEB1-
GFP constructs (Fig.3B). We also ensured that the length 
of wtEB1-GFP comets was similar to the endogenous EB1 
comets stained by immunofluorescence (2.5 ± 0.2 µm vs. 
2.2 ± 0.1 µm; p>0.05; Fig 3C and supplemental Fig 2C). 
We then measured that comet length was significantly 
increased to 3.9 ± 0.2 µm in T166A mutant cells, as 
compared with comets in wtEB1 cells that were 2.5 ± 0.2 
µm (p<0.001) (Fig.3C and Table 1). Consistently with 
this, we showed by live imaging fluorescence microscopy 
that the T166A mutation of EB1 significantly increased 
microtubule growth rate (15.9 ± 0.6 µm.min-1 vs. 10.6 
± 0.4 µm.min-1 in wtEB1 cells) and reduced catastrophe 
frequency (0.7 ± 0.1 µm-1 vs. 1.0 ± 0.1 µm-1 in wtEB1 
cells) (Table 2 and supplementary videos 1 and 2). The 
time of existence of EB1 binding sites at microtubule 
plus-ends, termed “decoration time”, was not different in 
the T166A-EB1 cells and in the wtEB1 cells (14.7 ± 0.2 
s and 14.2 ± 0.1 s respectively), since EB1 comet length 
and microtubule growth rate increased in a similar way 
(Table 2). The S155A mutation differently interfered with 
the microtubule system. EB1 comet length was conversely 
decreased to 1.9 ± 0.1 µm in S155A mutant cells (p<0.01; 
Fig.3C and Table 1), microtubule growth rate was only 
increased by 18 % (p<0.05) and the catastrophe frequency 
was not significantly modified (p>0.05) as compared 
with wtEB1 cells (Table 2 and supplementary videos 1 
and 3). In addition, decoration time of microtubule plus-
ends by EB1 S155A was decreased by 40 %, indicating 
that regulation of EB1 binding by phosphorylation on 
the S155 residue is distinct to what occurs when EB1 is 
phosphorylated on the T166 residue.
Lastly, we explored the relevance of EB1 
phosphorylation in microtubule-governed cell functions. 
T166A mutation led to slight increases in cell migration 
Figure 4: ROS-mediated EB1 phosphorylation is involved in MTA activities. (A) A549 cells were treated for 6 h with 2 nM 
of vincristine, paclitaxel and patupilone or combined with tiron, and lysed. Immunoprecipitation was performed as described in legend of 
Figure 3A. (B) Survival of wtEB1, EB1 T166A and EB1 S155A transfected U87-MG cells exposed to vincristine, measured by the MTT 
test. (C) Migration of U87-MG transfected cells (see details in Figures 3D legend) after a 6 h-treatment with vincristine 2 nM. Data are 
presented as mean ± S.E.M. Student’s t-test NS, p>0.05; **, p<0.05.
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Figure 5: ROS-mediated Akt/GSK3β pathway governs EB1 phosphorylation under MTA treatment. (A) Western blot 
analysis of expression and activity of Akt and GSK3β under 6 h-treatment with 2 nM of vincristine, paclitaxel or patupilone in A549 cells. 
Quantification of western blot bands, expressed as phospho/total protein ratio; α–tubulin was used as loading control. (B) Same experiment 
in cells exposed to patupilone, tiron or their combination. (C) A549 cells were treated for 6 h with 2 nM of vincristine or combined with 
SB216763. Immunoprecipitation was performed as described in Figure 3A legend. Data are presented as mean ± S.E.M. Student’s t-test *, 
p<0.05; **, p<0.01.
Oncotarget3416www.impactjournals.com/oncotarget
(+ 23 ± 7 %; p<0.05) and cell proliferation (up to + 15 
% at 96h) as compared to wtEB1 cells (Fig.3D and 3E). 
On the opposite, S155A mutation resulted in the decrease 
of the U87-MG cells migration (– 28 ± 6 %; p<0.05), as 
well as cell proliferation (– 11 % at 96h). Thus, depending 
on the residue targeted, EB1 phosphorylation results 
in quite opposite effects on microtubule dynamics and 
microtubule-governed cancer cell functions. 
ROS-mediated EB1 phosphorylation is involved 
in MTA activities.
To investigate whether EB1 phosphorylation 
play a role in MTA activity, we performed EB1 
immunoprecipitation from MTA-treated A549 cells 
(for 6 h). We showed that 6 h-treatment of vincristine, 
paclitaxel and patupilone increased EB1 phosphorylation 
Figure 6: GSK3β activation governs EB1 accumulation at microtubule plus-ends and MTA activities. (A) Double indirect 
immunofluorescence staining of EB1 (red) and α–tubulin (green) and quantification of EB1 comet length in A549 cells incubated with 
2 nM of vincristine, SB216763 or their combination for 6 h. Scale bars, 20μm. Magnified images: Scale bars, 5μm. (B) Detection of 
apoptosis in A549 cells by flow cytometry analysis of annexin-V and propidium iodide staining under 2 nM of patupilone, SB216763 or 
their combination for 6 h. (C) Measurement of transwell migration in U87-MG cells under 6 h-treatment of vincristine or patupilone 2 
nM, SB216763 or their combination. See Figure 3D legend for details. Data are presented as mean ± S.E.M. Student’s t-test *, p<0.05; **, 
p<0.01; ***, p<0.001.
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1.7, 2.5 and 3.2 times, respectively (Fig.4A, left and right 
panels). We revealed thus that patupilone-mediated EB1 
phosphorylation was governed by ROS, since it was 
suppressed by a simultaneous combination with tiron 
(Fig.4A, right panel). These data were validated in U87-
MG cells exposed to vincristine (Supplementary Fig.3).
In agreement with results obtained in U87-MG 
cells, vincristine decreased EB1 comet length by 60 
% in wtEB1-GFP transfected U87-MG cells (Table 1). 
Further, treatment also inhibited microtubule dynamics, 
via both a decrease in microtubule growth rate (– 30 %) 
and a huge increase in catastrophe frequency (+ 65 %) 
in wtEB1 cells (Table 2). Importantly, vincristine became 
almost completely ineffective in reducing comet length at 
microtubule plus-ends in EB1 T166A-GFP cells (Table 
1). In these mutant cells, the MTA-mediated increase in 
catastrophe frequency was limited to 26 %, while the 
decrease in microtubule growth rate was totally prevented 
by the T166A substitution (Table 2). On the opposite, 
the S155A mutation did not protect EB1 comet and 
microtubule dynamics from vincristine-induced damages 
(Tables 1 and 2).
We then explored if changes in EB1 phosphorylation 
influence MTA activities. As shown in Fig.4B, T166A cells 
were significantly less sensitive to cytotoxic effects of 
vincristine (for 72 h), with an IC50 value 4.4 fold-increased 
as compared to wtEB1 cells (9.2 ± 0.2 nM and 2.1 ± 0.4 
nM respectively; p<0.05). Moreover, T166A mutation of 
EB1 inhibited the anti-migratory activity of vincristine 
(for 6 h) (Fig.4C). In EB1 S155A mutated cells, unlike 
in T166A cells, vincristine cytotoxicity was maintained 
(IC50 value 2.1 ± 0.2 nM; Fig.4B), and vincristine anti-
migratory effects were similar as those measured in wtEB1 
cells (– 37 % and – 42 % respectively). 
Collectively, our results revealed that inhibition 
of EB1 T166 residue phosphorylation results in cancer 
cell insensitivity to MTA anti-microtubule activities, as 
well as resistance to MTA cytotoxic and anti-migratory 
properties. Conversely, MTAs are still effective in S155A 
mutant cells.
The Akt/GSK3β pathway governs EB1 
phosphorylation in MTA treated cells. 
We next sought to identify the molecular actors 
responsible for EB1 phosphorylation downstream of 
mitochondrial ROS generation. It has been reported 
that Microtubule-Associated Proteins (MAP) can be 
phosphorylated by GSK3β [40]. To investigate the 
involvement of the Akt/GSK3β signaling pathway in 
MTA-mediated EB1 phosphorylation, we first assessed 
the expression of phosphorylated S473 Akt, as well 
as S9 GSK3β. As shown in Fig.5A, 6 h-treatment with 
vincristine, paclitaxel or patupilone similarly led to a 
decrease by 50 % in the phosphorylated active form of 
Akt. Concomitantly, we showed a decrease in GSK3β 
phosphorylation (40 %, 37 % and 36 % respectively for 
the three MTAs), which is correlated with its activation. 
To determine whether ROS overproduction was involved 
in Akt inhibition, MTA-treated cells were simultaneously 
incubated with tiron. Interestingly, the O2
.- scavenger 
restored initial phospho-Akt and phospho-GSK3β levels 
(Fig.5B and Supplementary Fig.4A), indicating that MTA-
triggered ROS overproduction was responsible for Akt 
inactivation and, consequently, GSK3β activation. Then, 
to determine the role of GSK3β in EB1 phosphorylation, 
A549 cells were treated with MTA combined with the 
GSK3β specific inhibitor SB216763 during 6 h. As 
shown in Fig. 5C, SB216763 suppressed patupilone-
mediated phosphorylation of EB1, clearly pointing out 
that GSK3β is required to achieve EB1 phosphorylation. 
Consistently, SB216763 prevented EB1 accumulation 
at microtubule plus-ends in vincristine-treated A549 
cells (0.8 ± 0.1 µm and 2.6 ± 0.9 µm for vincristine and 
the combination respectively; p>0.05) (Fig.6A). Same 
results were obtained in U87-MG cells (Supplementary 
Fig.4B). Lastly, we showed that GSK3β was involved in 
both pro-apoptotic and anti-migratory activities of MTAs. 
For instance, SB216763 reduced 2.0 and 1.9 times A549 
cell death induced by a 48 h-treatment with vincristine 
and patupilone respectively (p<0.01; Fig. 6B). Likewise, 
we showed that combination of MTAs with SB216763 
resulted in a total suppression of the anti-migratory 
effect of vincristine and patupilone (Fig. 6C). Of note, 
we also analyzed AMPK activity, that appeared not to be 
involved in MTA activities (data not shown). Altogether, 
our results highlight a pivotal role for the ROS-modulated 
Akt/GSK3β pathway that, via EB1 phosphorylation and 
accumulation to microtubule plus-ends, governs MTA 
efficacy.
DISCUSSION
Understanding anticancer drug mechanism of action 
is of prime importance, not only for deciphering resistance 
processes but also for developing more convenient cancer 
therapy strategies. Here, we disclosed a novel mechanism 
by which generation of mitochondrial ROS suppresses 
microtubule dynamics, through Akt/GSK3β-mediated 
phosphorylation of EB1. Importantly, we identified this 
signaling bridge between mitochondria and microtubules 
as responsible for a considerable part of cancer cell 
response to MTA cytotoxic and anti-migratory activities.
EB1 is a conserved and ubiquitous member of 
the +TIPs family that regulates the growth and the 
polymerization of microtubules [41-42]. EB1 represents 
core element of a dynamic network at the growing 
microtubule plus-ends and regulate microtubule 
dynamics through recruitment of others +TIPs [24-25].
We previously showed that MTA anti-cancer and anti-
angiogenic efficacy correlated with EB1 comet disruption 
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in human neuroblastoma, glioblastoma and endothelial 
cells [30-32]. Processes underlying regulation of EB 
proteins binding to microtubule plus-ends have been the 
object of intensive investigations, and post-translational 
modifications such as detyronisation /retyrosination or 
acetylation of the EB1 C-terminal domain have been 
recently proposed [43-44]. The data currently available 
also reported phosphorylation of EB3 in endothelial and 
HeLa cells [33-34]. Phosphorylation of EB1 homologues 
(Bim1p and Mal3) has been shown in budding and fission 
yeasts [37-38], but there was still no evidence for such 
a process in mammalian cells. In the present study, we 
showed for the first time that EB1 was phosphorylated 
in human cancer cells of various tissue origins. By using 
phospho-defective mutants, we further identified Serine 
155 and Threonine 166 as the potential residues subjected 
to phosphorylation. These residues are located in the EB1 
linker region, which connects the N-terminal calponin 
homology domain with the C-terminal domain of EB 
proteins. The linker region of EB1 tightly contributes 
to its microtubule binding by promoting the Calponin-
Homology domain binding [24 and 45]. Here, we showed 
that phosphorylation on the S155 residue is required to 
EB1 accumulation at microtubule plus-ends, and both 
cancer cell migration and proliferation. Our results are 
supported by a recent study that linked EB3 stabilization 
during mitosis to its phosphorylation on S176 by Aurora 
kinases [46]. Phospho-defective S155 mutant decreased 
microtubule decoration time by EB1, suggesting that 
S155 phosphorylation may increase the time of existence 
or the number of EB1 binding sites at microtubule plus-
ends. Further, EB1 is now considered to specifically 
recognize both the tubulin GTP nucleotide state and the 
GTP hydrolysis-induced conformational states [22-23]. 
S155 phosphorylation may thus increase the time of 
existence of these intermediate forms by inhibiting GTP 
hydrolysis. The phospho-defective T166A mutant sharp 
contrasted with the S155A mutant since it promoted 
EB1 binding in a typical comet-like accumulation and 
induced microtubule growth through an increase cell 
proliferation and migration in cancer cells. Interestingly, 
EB3 phosphorylation on the S162 residue, which is also 
localized in the linker region, has been similarly identified 
to be required to destabilize the EB3 dimer and suppress 
microtubule growth [33]. Lastly, unlike S155 residue, 
T166 phosphorylation may appear to be required for the 
decrease of the EB1 decoration time of microtubules by 
MTAs. We characterized phosphorylation of EB1 on T166 
residue as a requisite molecular switch in MTA efficacy, 
from microtubule dynamics alterations to cytotoxic and 
anti-migratory consequences.
We identified the serine/threonine kinase GSK3β 
as responsible for MTA-triggered EB1 phosphorylation 
and decrease in EB1 accumulation at microtubule plus-
ends. EB1 can thus now be included to the class list of 
+TIP proteins that are substrates of GSK3β and associate 
with microtubules in a phosphorylation dependent 
manner [40]. Interestingly, we showed that GSK3β 
activation was essential for anti-migratory properties 
of MTA chemotherapy. Besides the well-known role of 
GSK3β in cell migration via APC [47], GSK3β-mediated 
phosphorylation of EB1 is a likely determining step 
in the migratory process. In support to this, previous 
works reported the importance of EB1 to stabilize 
microtubule plus-ends at cell cortex and target adhesion 
sites during migration [26, 30]. In the present study, 
we also showed that GSK3β participated to cancer cell 
death induced by MTAs. This may be related to the pro-
apoptotic properties of GSK3β, through phosphorylation 
of apoptotic regulators (such as Bax or Mcl-1) [48-49]. 
GSK3β activation resulted from Akt inactivation in 
MTA-treated cancer cells. Since the GSK3β selective 
inhibitor SB216763 only partially protected cells from 
MTA-induced cytotoxicity, we can easily hypothesize that 
inactivation of the pro-survival kinase Akt is also involved 
in the cell death process, by modulating either apoptotic 
actors or transcription factor activity [50]. Aberrantly high 
activation of Akt is a characteristic feature of resistance 
to multiple chemotherapies in a large variety of human 
cancers [51]. Akt inhibitors are currently evaluated in 
clinical trials, in combination with conventional cytotoxic 
drugs [52]. Especially, combination of perifosine or MK-
2206 with paclitaxel in ovarian, gastric and melanoma 
cancers has been recently shown to be a very promising 
approach [53-55]. In support to this, inhibition of the 
PI3K/Akt/mTOR pathway by NVP-BEZ235 potentiates 
effects of vincristine and reduces chemoresistance in in 
vitro and in vivo leukemia and sarcoma models [56-57]. 
By highlighting the key role of the Akt/GSK3β pathway 
in MTA mechanism of action, our results (i) support the 
interest for such therapeutic combinations to emphasize 
response to chemotherapy and overcome drug resistance, 
and (ii) give for the first time an explanation to their 
molecular mechanism. 
It has become clear that ROS can influence activity 
of numerous kinases and thereby control cell behavior [58]. 
Here, we showed that GSK3β activation in MTA-treated 
cells relies on mitochondrial ROS-mediated inhibition of 
upstream Akt. Molecular and chemical blockade of ROS 
overproduction ultimately led to cell insensitivity to both 
MTA cytotoxic and anti-migratory activities. Furthermore, 
very preliminary results have shown a deficit in ROS 
generation induction from mitochondria in multi-drug 
resistant cells (personal data). A more complex approach 
than only targeting of microtubules is thus warranted. 
Accordingly, a direct targeting of mitochondria by MTAs 
incorporated in novel mitochondriotropic nanocarriers 
has shown a gain in efficacy [59-61]. While mitochondria 
silencing has long been accepted as general consensus 
in cancer cells (Warburg effect), recent studies revealed 
that this intracellular network is still functional, even in 
cells that shifted cellular energy metabolism to glycolysis 
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[62]. Hence, a potential therapeutic strategy may consist in 
the re-activation of mitochondrial oxidative metabolism, 
including by inhibiting glycolysis [63-64]. Interestingly, 
the glycolytic phenotype of cancer cells has been reported 
to be induced by Akt upregulation [65]. A very recent 
study supports this link between energetic metabolism and 
Akt pathway, since GSK3β has been reported to potentiate 
mitochondria biosynthesis stimulation induced by a 
2-Desoxy-Glucose-mediated inhibition of glycolysis [66]. 
Thus, combining MTAs to anti-Akt targeted therapies (as 
discussed above) might also be efficient through induction 
of a switch from a glycolytic to an oxidative phenotype in 
cancer cells.
To conclude, by characterizing a novel 
phosphorylation-mediated regulation of EB1, the present 
study improves our fundamental knowledge about this 
oncogenic protein, which influences processes involved 
in cancer progression. We also showed the role played by 
mitochondrial ROS to initiate such a regulatory process 
of EB1 that leads to MTA efficacy, pointing out the need 
to reexamine the current dogma of microtubule targeting 
by MTAs. Lastly, our work provides a strong mechanistic 
rational to the promising therapeutic strategies that 
combine MTA-based conventional chemotherapy with 
anti-Akt targeted therapies.
MATERIAL AND METHODS
Cell culture
Human non-small lung carcinoma (A549), 
neuroblastoma (SK-N-SH) and gliobastoma (U87-MG) 
cells were obtained from ATCC (Manassas, VA, USA). 
They were grown in RPMI-1640 medium or in MEM 
medium supplemented with 1% L-glutamine (Lonza, 
Levallois-Perret, France), 10 % fetal calf serum (Lonza), 
1 % penicillin/streptomycin (Sigma-Aldrich, Saint-Louis, 
MO, USA). Rho-negative (ρ(-)) SK-N-SH cells were 
obtained by incubating parental (wt) SK-N-SH cells for 8 
weeks with ethidium bromide as previously described [4]. 
All cell lines were routinely maintained in culture at 37°C 
and 5 % CO2 and regularly screened to ensure the absence 
of mycoplasma contamination. Cells were seeded (1.9 
x 104 cells/cm2 for A549, 3.3 x 104 cells/cm2 for SK-N-
SH and 1.3 x 104 cells/cm2 for U87-MG) 24 hours before 
treatment. 
Drugs and reagents
Stock solution of paclitaxel (Novasep synthesis) 
was prepared in dimethyl sulfoxide (DMSO) (Sigma-
Aldrich) while vincristine (Lilly, Strasbourg, France) 
and patupilone (Sigma-Aldrich) were prepared in sterile 
distilled water. Stock solutions of tiron and potassium 
cyanide (KCN) were prepared in sterile distilled water, 
while rotenone was prepared in DMSO. SB216763 was 
purchased from Sigma-Aldrich. All these solutions were 
freshly diluted in the culture medium for experiments.
Cytotoxicity test
Cells were seeded in 96-well plates to be treated 
during 72 hours with MTAs. Cell survival was measured 
by using the colorimetric MTT assay (Sigma-Aldrich) as 
we previously performed [14, 32]. 
Measurement of Reactive Oxygen Species
Cells were treated with MTAs, antioxidants, or 
their simultaneous combination for 6 hours. KCN and 
rotenone, specific inhibitors of complex I and IV of the 
mitochondrial respiratory chain were used at 100µM 
and 100nM respectively, and the O2
.- scavenger tiron at 
2mM. Hydrogen peroxide production was evaluated by 
H2-DCF-DA fluorescence (Life Technologies, Carlsbad, 
USA) in 96-well black plates. Formation of DCF 
fluorescent product was measured in a Fluoroskan Ascen 
FL plate reader as previously described [4]. Superoxide 
ion generation was measured by WST-1 colorimetric test 
(Roche, Mannheim, Germany). After 30min of WST-1 
incubation (500µM), absorbance was measured at 450nm 
with a Multiskan plate reader (Ascent). For each assay, the 
reading was corrected for the estimated cell number: cells 
were fixed with 1 % glutaraldehyde (Sigma–Aldrich) and 
stained with 1 % Crystal-violet (Sigma–Aldrich) solution 
in 20 % Methanol (Sigma–Aldrich). 
Indirect immunofluorescence analysis
Cells were grown on 8-well chamber slides (Labtek, 
Thermo Scientific, Roskilde, Denmark), precoated for 1 
hour with fibronectin (10 μg/ml) for U87-MG or with 
type I collagen (30µg/ml) for SK-N-SH (Sigma Aldrich), 
to be treated for 6 hours with MTAs and inhibitors. As 
previously described [32], cells were incubated with 
the anti-EB1 (clone 5; BD Biosciences, San Jose, CA) 
and α-tubulin (clone DM1A; Sigma Aldrich) primary 
antibodies, and then with Alexa488 or 568-conjugated 
secondary antibodies (Molecular Probes). Staining was 
observed using either a Leica DM-IRBE microscope or 
a Leica TCS SP5 confocal laser-scanning microscope 
(Leica, Heidelberg, Germany). Images were acquired 
using Metamoph software or the Leica Confocal software, 
and were processed using Image J software. For each 
experimental condition, at least 400 EB1 comets (in 40 
cells) were examined to measure their length.
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Western blot analysis
Cells were lysed after 6 hours treatment in 
RIPA buffer (Tris-HCl 50mM pH 8.0, NaCl 250mM, 
Triton-X100 0.1 %) with a cocktail of proteases 
and phosphatases inhibitors (Sigma-Aldrich) added 
freshly. Protein concentrations were determined using 
the Bio-Rad Protein Assay (Bio-Rad laboratories, 
France). Proteins were separated by SDS-PAGE and 
electrotransferred onto a nitrocellulose membrane. 
Primary antibodies used were directed against EB1 (clone 
5; BD Biosciences), α-tubulin (clone DM1A, Sigma 
Aldrich), Ser 473 phospho-Akt, total Akt, Ser 9 phospho-
GSK3β (Cell Signaling, Boston, USA), total GSK3β 
(Life Technologies). Peroxydase-conjugated secondary 
antibodies (Jackson Immunoresearch, Baltimore, USA) 
and chemiluminescence detection kit (Millipore) were 
used for visualization, and signal quantification was done 
with Image J software. 
EB1 immunoprecipitation
Cells were lysed in modified RIPA buffer (Tris-
HCl 50mM pH 7.5, NaCl 150mM, 1mM EDTA, 2.5mM 
MgCl2) with a cocktail of proteases and phosphatases 
inhibitors added freshly. Prior to immunoprecipitation, 
5µg of anti-EB1 antibody (clone 5; BD Biosciences) 
was added to 50µl of protein G-Sepharose beads (Sigma-
Aldrich) for 1 hour. Then, an equal amount of each protein 
lysate was incubated with the previous mixture and rotated 
overnight at 4°C. After centrifugation, the supernatant 
was removed and the immune complex was analyzed by 
Western blot with primary antibodies against EB1 (clone 
5; BD Biosciences) and serine, threonine and tyrosine 
phosphorylated proteins (clone SPM101; Abcam). 
Proliferation test
Cells were grown in 96-well plates, and were fixed 
at different times with 1 % glutaraldehyde and stained with 
a 1 % Crystal-violet solution in 20 % Methanol. The stain 
was eluted with DMSO and absorbance was measured at 
600nm with a Multiskan Ascent plate reader. 
Annexin V-FITC/PI staining assay
Following a 24 and 48 hours treatment, cells 
were exposed to Apoptosis/Necrosis Detection Kit 
(BD Biosciences) used according to the manufacturer’s 
instructions. The fluorescence was analyzed by flow 
cytometry analysis (FacSort of Becton Dickinson 
Immunocytometry Systems, Inc., San Jose, CA) as 
previously described [67]. 
Transwell migration assay
Cells were allowed to migrate for 6 hours in 
a transwell migration chamber (0.8 μm filter, BD 
Bioscience); for details see our previous work [32]. 
Pictures of the lower sides of filters were taken with 
an Olympus microscope. Six fields per condition were 
imaged and transmigrated cells were counted. Results 
were expressed as a percentage of transmigrated cells 
compared with no treatment condition. 
Plasmid constructs and transfection
pEB1-T166 and S155 were derived from pEB1-
GFP (human EB1 in pEGFP N1 to express EB1-GFP) 
by mutation of the T166 or/and S155 of EB1 using the 
Quickchange II site directed mutagenesis kit (Agilent 
Technologies, Les Ulis, France) according to the 
manufacturer’s protocol. The T166 and S155 were both 
replaced by an A by mutation. The primers (mutations are 
underlined) used were: 
T166 site (561 bp from origin): 
MuEB1T166 F 5’ 
GAGGCCCATCTCAGCACAGAGAACC 3’
MuEB1T166 R 5’ 
GGTTCTCTGTGCTGAGATGGGCCTC 3’
S155 site (527 bp from origin): 
MuEB1S155 F 
5’CCTCTCACTGCTAGCAGTGCAGCTC 3’
MuEB1S155 R 5’ 
GAGCTGCACTGCTAGCAGTGAGAGG 3’
The resulting mutant cDNA (pEB1–T166A and 
pEB1–S155A) constructs were sequenced to confirm their 
integrity before use (Beckman Coulter Genomics). U87-
MG cells were then transiently transfected with 3µg pEB1, 
pEB1–T166A or pEB1–S155A using Lipofectamine 
2000 reagent (Life Technologies) according to the 
manufacturer’s instructions. To establish stable clones, 
cells were selected with 0.8 µg/ml geneticin (Life 
Technologies). 
Fluorescent time-lapse video microscopy
Time-lapse acquisitions for microtubule dynamics 
experiments (wtEB1-GFP, T166A-GFP and S155A-GFP 
U87-MG cells) were performed with a Leica DM-IRBE 
equipped with a 60X / NA 1.49 objective lens. Thirty-
one images per cell were acquired at 2-s intervals using 
a digital camera (CCD camera Coolsnap FX; Princeton 
Instruments). Analysis of microtubule dynamics was 
performed using the manual tracking personalized 
plug-in for Image J software. Position of EB1 comets 
was detected by thresholding a filtered image and the 
centroids of individual comets were followed over time. 
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Changes in length exceeding 0.067 µm were considered 
as growth events. Catastrophe frequency was calculated 
for each individual comet tracked, and corresponds to the 
inverse of the total length of growth. Decoration time was 
calculated by dividing EB1 comet length by microtubule 
growth rate. At least 30 microtubules were analyzed for 
each experimental condition.
Statistical analysis
Each experiment was performed at least in 
triplicate. Data are presented as mean ± S.E.M. Statistical 
significance was tested using Student’s t test. A significant 
difference between two conditions was recorded for *, 
p<0.05; **, p<0.01; ***, p<0.001.
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